Cited by 38Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Sequence Variants of Toll Like Receptor 4 and Late-Onset Alzheimer's Disease

Open access
Chen, Yen-Ching, Yip, Ping-Keung, Huang, Yi-Ling, Sun, Yu, Wen, Li-Li, Chu, Yi-Min, Chen, Ta-Fu·2012·PLoS ONE

Abstract

BACKGROUND: Toll like receptor 4 (TLR4) has been related to inflammation and beta-amyloid deposition in Alzheimer's disease (AD) brain. No study has explored the association between haplotype-tagging single nucleotide polymorphisms (htSNPs) of TLR4 and AD risk previously and ApoE e4 status alone showed low sensitivity in identifying late-onset AD (LOAD) patients. METHODS: A total of 269 LOAD patients were recruited from three hospitals in northern Taiwan (2007-2010). Controls (n = 449) were recruited from elderly health checkup and volunteers of the hospital during the same period of time. Five common (frequency≥5%) TLR4 htSNPs were selected to assess the association between TLR4 polymorphisms and the risk of LOAD in the Chinese ethnic population. RESULTS: Homozygosity of TLR4 rs1927907 was significantly associated with an increased risk of LOAD [TT vs. CC: adjusted odds ratio (AOR) = 2.45, 95% confidence interval (CI) = 1.30-4.64]. After stratification, the association increased further in ApoE e4 non-carriers (AOR = 3.07) and in hypertensive patients (AOR = 3.60). Haplotype GACGG was associated with a decreased risk of LOAD (1 vs. 0 copies: AOR = 0.59, 95% CI = 0.36-0.96; 2 vs. 0 copies: AOR = 0.31, 95% CI = 0.14-0.67) in ApoE e4 non-carriers. ApoE e4 status significantly modified this association (p(interaction) = 0.01). These associations remained significant after correction for multiple tests. CONCLUSIONS: Sequence variants of TLR4 were associated with an increased risk of LOAD, especially in ApoE e4 non-carriers and in hypertensive patients. The combination of TLR4 rs1927907 and ApoE e4 significantly increased the screening sensitivity in identifying LOAD patients from 0.4 to 0.7.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0050771

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Sequence variants of the LPS-receptor TLR4 and the LPS-binding receptor TREM2 are associated with an increased risk of Alzheimer's disease.

    “Sequence variants of the LPS-receptor TLR4 [84] and the LPS-binding receptor TREM2 [22] are also associated with an increased risk of AD, indicating additional genetic links between AD and endotoxin.”

    From The endotoxin hypothesis of neurodegeneration (2019) · cites this paper as [84]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 53 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Chen, Y.-C., Yip, P.-K., Huang, Y.-L., Sun, Y., Wen, L.-L., Chu, Y.-M., & Chen, T.-F.
Affiliations
  • National Taiwan University (TW)
  • Fu Jen Catholic University (TW)
  • En Chu Kong Hospital (TW)
  • National Taiwan University Hospital (TW)
Corresponding author
Chen, Yen-Ching
Venue
PLoS ONE
Published
2012-12-18
Volume
7
Issue
12
Pages
e50771
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2012612081
Cited by
38
References
53
Citations by year
2026: 1 · 2025: 2 · 2023: 3 · 2021: 1 · 2020: 6 · 2019: 5 · 2018: 2 · 2017: 1 · 2016: 6 · 2015: 6 · 2014: 2 · 2013: 2 · 2012: 1
FWCI
2.36
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
National Science Council (97‐2314‐B‐002‐168‐MY3, 96-2314-B-002-197)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
TLR4, late-onset Alzheimer's disease, single nucleotide polymorphisms, haplotype tagging, APOE ε4, genetic susceptibility, hypertension, Chinese population
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Dementia, Female, Genotype, Haplotypes, Heterozygote, Homozygote, Humans, Hypertension, Inflammation, Genetic Linkage, Male, Models, Genetic, Surveys and Questionnaires, Risk, Taiwan, Odds Ratio, Case-Control Studies, Age of Onset, Polymorphism, Single Nucleotide, Toll-Like Receptor 4, Apolipoprotein E4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review